Utility of 18F-fluoroestradiol PET / CT in the differential diagnosis of estrogen receptor-positive breast cancer: case series
https://doi.org/10.17650/1994-4098-2021-17-2-75-80
Abstract
Breast cancer is one of the most common female cancers and the leading cause of cancer death in women. The method of positron emission tomography, combined with computed tomography, makes it possible to assess not only anatomical and structural, but also metabolic changes in tumor tissue. The increased accumulation of 18F-fluoroestradiol in the pathological focus correlates with the estrogen receptor-positive status of the tumor, which is confirmed by tissue immunohistochemistry studies. The receptor status of a tumor formation fundamentally affects the choice of therapeutic tactics. The presented clinical examples demonstrate the capabilities of positron emission tomography, combined with computed tomography, with 18F-fluoroestradiol in the diagnosis of the estrogen receptor-positive tumor lesions.
About the Authors
A. V. Parnas
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993, Russia
A. I. Pronin
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478, Russia
V. S. Ilyakov
Russian Medical Academy of Postgraduate Education, Ministry of Health of Russia
Russian Federation
Russian Federation
Build. 1, 2 / 1 Barrikadnaya St., Moscow 125993, Russia
N. A. Meshcheryakova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478, Russia
Z. Kh. Kamolova
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478, Russia
D. I. Nevzorov
N.N. Blokhin Russian Cancer Research Center, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478, Russia
References
1. Malignant tumors in Russia in 2017 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: P.A. Herzen Moscow Oncology Research Institute – a branch of the National Medical Research Radiological Center, Ministry of Health of Russia, 2018. 250 p. (In Russ.).
2. Waks A.G., Winer E.P. Breast cancer treatment: A review. JAMA 2019;321(3): 288–300. DOI: 10.1001/jama.2018.19323.
3. Hospers G.A., Helmond F.A., de Vries E.G. et al. PET imaging of steroid receptor expression in breast and prostate cancer. Curr Pharm Des 2008;14:3020–32. DOI: 10.2174/138161208786404362.
4. Bonacho T., Rodrigues F., Liberal J. Immunohistochemistry for diagnosis and prognosis of breast cancer: a review. Biotech Histochem 2019;1–21. DOI: 10.1080/10520295.2019.1651901.
5. Seenu V., Sharma A., Kumar R. et al. Evaluation of estrogen expression of breast cancer using 18F-FES PET CT-A novel technique. World J Nucl Med 2020;19:233–9.
6. Dehdashti F., Mortimer J.E., Siegel B.A. et al. Positron tomographic assessment of estrogen receptors in breast cancer: Comparison with FDG‐PET and in vitro receptor assays. J Nucl Med 1995;36:1766–74.
7. Gemignani M.L., Patil S., Seshan V.E. et al. Feasibility and predictability of perioperative pet and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med 2013;54:1697–1702. DOI: 10.2967/jnumed.112.113373.
8. Kurland B.F., Peterson L.M., Lee J.H. et al. Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res 2017;23:407–15. DOI: 10.1158/1078-0432.CCR-16-0362.
9. Liao G.J., Clark A.S., Schubert E.K. et al. 18F‐fluoroestradiol PET: Current status and potential future clinical applications. J Nucl Med 2016;57:1269–75. DOI: 10.2967/jnumed.116.175596.
10. Peterson L., Manohar P., Wu V. et al. 18F‑Fluoroestradiol (FES) and 18F‑Fluorodeoxyglucose (FDG) PET imaging in male breast cancer. J Nucl Med 2018;59(Suppl 1):54. DOI: 10.1158/1078-0432.CCR-16-0362.
Review
For citations:
Parnas A.V., Pronin A.I., Ilyakov V.S., Meshcheryakova N.A., Kamolova Z.Kh., Nevzorov D.I. Utility of 18F-fluoroestradiol PET / CT in the differential diagnosis of estrogen receptor-positive breast cancer: case series. Tumors of female reproductive system. 2021;17(2):75‑80. (In Russ.) https://doi.org/10.17650/1994-4098-2021-17-2-75-80
Views:
430
Email this article 